Andrew von Eschenbach News
Most Popular Andrew von Eschenbach Story
ALSO NOTED: Rumor Mill: AstraZeneca a possible Shire suitor; Cardiome baits hook for partners; Vertex shares keep sliding; and
> Shire is suddenly the talk of the town as investors and investment banks publicly mull a match-up with AstraZeneca. Read more...
Latest Headlines
- April 4, 2008
- September 20, 2007
- July 27, 2007
- January 30, 2007
- December 7, 2006
- November 30, 2006
- September 19, 2006
- September 14, 2006
- August 23, 2006
- August 17, 2006
- August 8, 2006
- July 9, 2006
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
